AREVIR-GenaFor-Meeting 2011

Program

Donnerstag, 05. Mai 2011

Zeit	Vorträge
09:00 - 09:15	Opening Comments U. B. Kaup / Stiftung caesar
09:15 - 10:45	Chair: Dieter Glebe, Maria Neumann-Fraune Hepatitis B HBV: therapy updates HBV: Resistance testing, Determination of Genotype Escape-Variants Speakers: Bastian Beggel, Florian van Bömmel, Wolfram Gerlich
	Long Term Management of chronical HBV Slides missing Florian van Bömmel
	Role of mutations outside the RT-domain of HBV polymerase on antiviral resistance Dieter Glebe
	Update on geno2pheno[HBV] Bastian Beggel
	Covalently Closed Circular (ccc) DNA in the Clinical Setting Karsten Wursthorn
10:45 - 11:00	Coffee break
11:00 - 12:15	Chair: Tobias Goeser / Rolf Kaiser Hepatitis C HCV: Basics HCV: new drugs HCV: Resistance testing
	Hepatitis C Virus: Basics & Antiviral Therapy Ralf Bartenschlager
	Hepatitis C Virus: Pre PI Screening Project Anna Maria Sikorski
	Interpreting HCV genotypes Sven-Eric Schelhorn
	HCV NS3/4A protease inhibitors for the treatment of HCV infected patients Oliver Lenz
	Slides missing Müller (MSD)
	The Road Ahead: Reassessing Unmet Needs in HCV Management Stefan Zeuzem (Rolf Kaiser)
12:15 - 13:30	Chair: Thomas Klimkeit / Nadine Lübke Coreceptor Speakers: Valentina Svicher, Alexander Thielen, Nico Dybowski, Björn Jensen
	Tropism Testing: Facts - Challenges - Vision Thomas Klimkeit
	geno2pheno [coreceptor] Alexander Thielen
	Correlating Genotypic Tropism Prediction with the Virological Response to MVC Treatment Nikolaj Dybowski
	Physicochemical and structural properties determining HIV-1 coreceptor usage Kasia Bozek
	CCR5 Antagonists in Clinical Practice Björn Jensen
	Adding HIV-1 genetic variability to the study of the local epidemic and co-receptor usage in recently diagnosed individuals Kristen Chalmet
	Tropism Testing: Who needs a Phenotype... Thomas Klimkeit
	Enhancement of genotypic test for tropism determination: the role of the oscar project Claudia Alteri
	European Coreceptor Analyses Rolf Kaiser
13:30 - 14:30	Lunch
14:30 - 15:15	Chair: Rolf Kaiser HIV
	Introduction to the European Society for Antiviral Resistance (ESAR) Annemarie Wensing
	Characterization of the resistance profile of TMC278 Johan Vingerhoets
	ABL - TherapyEdge Chalom Sayada
15:15 - 15:40	Chair: Herbert Pfister HIV - resistance
	Predicting response to HIV therapy by computational modeling of large clinical datasets Brendan Larder
15:30 - 17:30	Chair: Lutz Gürtler / Patrick Braun HIV Low viral load Qiagen, Roche, Siemens and Abbott assays presented Presentation low viral load assays Clinical case
	Low level viremia Stefan Esser
	VERSANT HIV-1 RNA 1.0 (kPCR) Anne Beyou-Zuliani
	QIAsymphony RGQ - The Power of Flexibility Gavin Wall
	Highly sensitive detection of HIV-1 viral load - COBAS® AmpliPrep/COBAS® Dorothea Sizmann
	Abbott RealTime HIV-1 Birgit Reinhardt
	Low-level Viremia below 50 cps/mL in treated HIV-infected patients predicts viral load rebound above 400 cps/mL independently of adherence levels Paola Vitiello
	Comparison of HIV-1 Viral Load samples between RealTime (Abbott) and COBAS TaqMan (Roche) Gudrun Naeth
	HIV-GRADE Hauke Walter
17:30 - 18:30	Chair: Sandra Müller Basics science Speakers: Evrim Anadol, Renate König, Carsten Münk
	Comparative study of intra-host HIV evolution: Emergence of viral diversity Miriam Carbon-Mangels
	HIV-1's different ways to survive against hostile APOBEC3 proteins Carsten Münk

Freitag, 06. Mai 2011

Zeit	Vorträge
09:00 - 10:00	Chair: Hauke Walter, Alexander Thielen New sequencing technologies replacing Sanger seq?
	Next generation sequencing technologies replacing Sanger sequencing? Martin Däumer
10:00 - 11:00	Chair: Mark Oette / Eugen Schülter Databases and projects RKI-CLINSERV/seroconverter study Data from the RESINA cohort
	Trends in transmission of resistant HIV and HIV-1 subtypes Claudia Kücherer
	Antiretroviral treatment patterns in the ClinSurv HIV Cohort Barbara Bartmeyer
11:00 - 13:00	Workshop Protocols, interpretation, clinical application
	1.) CoreceptorSlides missing Martin Obermeier, Alexander Thielen, Ramona Pauli
	2.) HBVSlides missing Andreas Erhardt, Jens Verheyen, Bastian Beggel
	3.) HCV Slides missing Saleta Sierra-Aragon, Christoph Boesecke, Sven Eric Schelhorn
13:00 - 13:30	Chair: Rolf Kaiser Is resistance disappearing ?
	Is HIV-1 drug resistance disappearing ? Andrea De Luca
13:30 - 14:30	Lunch
14:30 - 18:00	Chair: Maurizio Zazzi, Francesca Incardona International EuResist meeting Therapy-Naïve-Tools Prediction based on therapy history HIV resistance, treatment perspectives and data collection in Russia, Tanzania, Vietnam, Kenya, Ethiopia, India
	EuResist present and future Anders Sonnerborg
	Applying HIV Bioinformatics to Clinical Practice: What Will The Future Bring? Thomas Lengauer, Max-Planck-Institute for Informatics (Saarbrücken)
	A Tool for Predicting the Success of First-Line Antiretroviral Therapies Alejandro Pironti, Max-Planck-Institute for Informatics (Saarbrücken)
	History-aware models for predicting outcomes of HIV combination therapies Jasmina Bogojeska, Max-Planck-Institute for Informatics (Saarbrücken)
	Impact of peer support on survival, virological treatment failure and resistance among HIV naïve patients - a randomized control trial in Vietnam Do Duy Cuong, Karolinska Institutet Stockholm (Sweden)
	Overview of HIV, Treatment, Resistance and Prospective Data Collection in Tanzania Doreen Mloka, Muhimbili University of Health Sciences (Tanzania)
	Historical Background of HIV in Kenya Washington Njogu, Ruaraka Neema Hospital (Kenya)
	HIV treatment perspectives, resistance and data collection in Kenya Matilu Mwau, KEMRI (Kenya)
	HIV resistance, treatment perspectives, and data collection in Ethiopia Wondwossen Amogne
	HIV treatment & ARV resistance issues in India Dr. N. Kumarasamy, Chief Medical Officer, YRG Centre for AIDS Research and Education VHS (Chennai, India)
	HIV-1 Molecular Epidemiology and Drug Resistance in India Ujjwal Neogi, St. John’s Medical College and Hospital (Bangalore, India)
18:00 - 18:30	Summary Rolf Kaiser

Download Program (PDF)

Welcome to Genafor − Open Services for Medical Research

AREVIR-GenaFor-Meeting 2011

Program

Donnerstag, 05. Mai 2011

Freitag, 06. Mai 2011